Doxorubicin-loaded nanoparticles: New advances in breast cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 1058-1070

  Prados, Jose ^a   Melguizo, Consolación ^a   Ortiz, Raul ^b   Vélez, Celia ^a   Alvarez, Pablo J ^a   Arias, Jose L ^a   Ruíz, Maria A ^a   Gallardo, Visitacion ^a   Aranega, Antonia ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

Breast cancer; Chitosan; Cytotoxic drugs; Doxorubicin; Drug resistance; Nanoparticles; P glycoprotein

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHITOSAN; DOXORUBICIN; HYALURONIC ACID; LUNG RESISTANCE PROTEIN; MAGNETIC NANOPARTICLE; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; N (2 HYDROXYPROPYL) METHACRYLAMIDE COPOLYMER; NANOPARTICLE; POLOXAMER; POLYMER LIPID HYBRID NANOPARTICLE; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TOCOFERSOLAN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER THERAPY; CELL STRAIN MCF 7; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC);

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST; BREAST NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NANOPARTICLES; P-GLYCOPROTEIN;

EID: 84872249661     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803529646     Document Type: Article

References (143)

1. Harbeck, N.; Salem, M.; Nitz, U.; Gluz, O.; Liedtke, C. Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treat. Rev., 2010, 36(8), 584-594.
2. Beardsley, T. A war not won. Sci. Am., 1994, 270(1), 130-138.
3. Henderson, I.C.; Canellos, G.P. Cancer of the breast: the past decade (second of two parts). N. Engl. J. Med., 1980, 302(2), 78-90.
4. Gudkov, A.V.; Zelnick, C.R.; Kazarov, A.R.; Thimmapaya, R.; Suttle, D.P.; Beck, W.T.; Roninson, I.B. Isolation of genetic suppressor elements, inducing resistance to topoisomerase IIinteractive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl. Acad. Sci. U.S.A., 1993, 90(8), 3231-3235.
5. Momparler, R.L.; Karon, M.; Siegel, S.E.; Avila, F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res., 1976, 36(8), 2891-2895.
6. Yu, J.J.; Lee, H.A.; Kim, J. H.; Kong, W.H.; Kim, Y.; Cui, Z.Y.; Park, K.G.; Kim, W.S.; Lee, H.G.; Seo, S.W. Bio-distribution and anti-tumor efficacy of PEG/PLA nano particles loaded doxorubicin. J. Drug Target, 2007, 15(4), 279-284.
7. Takemura, G.; Fujiwara, H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis., 2007, 49(5), 330-352.
8. Wang, Y.; Wei, X.; Zhang, C.; Zhang, F.; Liang, W. Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects. Therapeutic Delivery, 2010, 1(2), 273-287.
9. Sahoo, S.K.; Parveen, S.; Panda, J.J. The present and future of nanotechnology in human health care. Nanomedicine, 2007, 3(1), 20-31.
10. Park, J.H.; Lee, S.; Kim, J.-H.; Park, K.; Kim, K.; Kwon, I.C. Polymeric nanomedicine for cancer therapy. Prog. Poly. Sci., 2008, 33(1), 113-137.
11. Oberdorster, G.; Maynard, A.; Donaldson, K.; Castranova, V.; Fitzpatrick, J.; Ausman, K.; Carter, J.; Karn, B.; Kreyling, W.; Lai, D.; Olin, S.; Monteiro-Riviere, N.; Warheit, D.; Yang, H. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol., 2005, 2, 8.
12. Cho, K.; Wang, X.; Nie, S.; Chen, Z.G.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14(5), 1310-1316.
13. Parveen, S.; Sahoo, S.K. Polymeric nanoparticles for cancer therapy. J. Drug Target, 2008, 16(2), 108-123.
14. Freitas, C.; Muller, R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 1999, 47(2), 125-132.
15. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul., 2001, 41, 189-207.
16. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2002, 2(10), 750-763.
17. Wu, C.P.; Hsieh, C.H.; Wu, Y.S. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol. Pharm., 2011, 8(6), 1996-2011.
18. Li, Y.; Yuan, H.; Yang, K.; Xu, W.; Tang, W.; Li, X. The structure and functions of P-glycoprotein. Curr. Med. Chem., 2010, 17(8), 786-800.
19. Haimeur, A.; Conseil, G.; Deeley, R.G.; Cole, S.P. The MRPrelated and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab.100, 2004, 5(1), 21-53.
20. Zhou, S.F.; Wang, L.L.; Di, Y.M.; Xue, C.C.; Duan, W.; Li, C.G.; Li, Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem., 2008, 15(20), 1981-2039.
21. Cole, S.P.C.; Bhardwaj, G.; Gerlach, J.H.; Mackie, J.E.; Grant, C.E.; Almquist, K.C.; Stewart, A.J.; Kurz, E.U.; Duncan, A.M.; Deeley, R.G. Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line. Science, 1992, 258(5088), 1650-1654.
22. Steiner, E.; Holzmann, K.; Elbling, L.; Micksche, M.; Berger, W. Cellular functions of vaults and their involvement in multidrug resistance. Curr. Drug Targets, 2006, 7(8), 923-934.
23. Ni, Z.; Bikadi, Z.; Rosenberg, M.F.; Mao, Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr. Drug Metab., 2010, 11(7), 603-617.
24. Germano, S., O'Driscoll, L. Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr. Cancer Drug Targets, 2011, 9(3), 398-418.
25. Dong, X., Mumper, R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond), 2010, 5(4), 597-615.
26. Shieh, M.J.; Hsu, C.Y.; Huang, L.Y.; Chen, H.Y.; Huang, F.H.; Lai, P.S. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J. Control Release, 2011, 152(3), 418-425.
27. Gao, Y.; Chen, L.; Zhang, Z.; Chen, Y.; Li, Y. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials, 2011, 32(6), 1738-1747.
28. Kang, K.W.; Chun, M.K.; Kim, O.; Subedi, R.K.; Ahn, S.G.; Yoon, J.H.; Choi, H.K. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine, 2010, 6(2), 210-213.
29. Chen, C.H.; Cuong, N.V.; Chen, Y.T.; So, R.C.; Liau, I.; Hsieh, M.F. Overcoming multidrug resistance of breast cancer cells by the micellar doxorubicin nanoparticles of mPEG-PCL-graft-cellulose. J. Nanosci. Nanotechnol., 2011, 11(1), 53-60.
30. Li, P.Y.; Lai, P.S.; Hung, W.C.; Syu, W.J. Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells. Biomacromolecules, 2010, 11(10), 2576-2582.
31. Muller, R.H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-177.
32. Chawla, J.S.; Amiji, M.M. Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int. J. Pharm., 2002, 249(1-2), 127-138.
33. Zhang, W.; Liu, J.; Li, S.; Chen, M.; Liu, H. Preparation and evaluation of stealth Tashinone IIA-loaded solid lipid nanoparticles: Influence of Poloxamer 188 coating on phagocytic uptake. J. Microencapsul., 2008, 25(3), 203-209.
34. Zhang, X.; Pan, W.; Gan, L.; Zhu, C.; Gan, Y.; Nie, S. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull. (Tokyo), 2008, 56(12), 1645-1650.
35. Santander-Ortega, M.J.; Stauner, T.; Loretz, B.; Ortega-Vinuesa, J.L.; Bastos-Gonzalez, D.; Wenz, G.; Schaefer, U.F.; Lehr, C.M. Nanoparticles made from novel starch derivatives for transdermal drug delivery. J. Control Release, 2010, 141(1), 85-92.
36. Wu, L.; Tang, C.; Yin, C. Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev. Ind. Pharm., 2010, 36(4), 439-448.
37. Ying, X.-Y.; Cui, D.; Yu, L.; Du, Y.-Z. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydrate Polymers, 2011, 84(4), 1357-1364.
38. Kockisch, S.; Rees, G.D.; Young, S.A.; Tsibouklis, J.; Smart, J.D. Polymeric microspheres for drug delivery to the oral cavity: an in vitro evaluation of mucoadhesive potential. J. Pharm. Sci., 2003, 92(8), 1614-1623.
39. Agarwal, A.; Covic, L.; Sevigny, L.M.; Kaneider, N.C.; Lazarides, K.; Azabdaftari, G.; Sharifi, S.; Kuliopulos, A. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol. Cancer Ther., 2008, 7(9), 2746-2757.
40. Lee, Y.C.; Lee, R.T. Carbohydrate-Protein Interactions-Basis of Glycobiology. Acc. Chem. Res., 1995, 28(8), 321-327.
41. Dennis, J.W.; Granovsky, M.; Warren, C.E. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta, 1999, 1473(1), 21-34.
42. Johns, T.G.; Mellman, I.; Cartwright, G.A.; Ritter, G.; Old, L.J.; Burgess, A.W.; Scott, A.M. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J., 2005, 19(7), 780-782.
43. Budzynska, R.; Nevozhay, D.; Kanska, U.; Jagiello, M.; Opolski, A.; Wietrzyk, J.; Boratynski, J. Antitumor activity of mannanmethotrexate conjugate in vitro and in vivo. Oncol. Res., 2007, 16(9), 415-421.
44. Wadhwa, M.S.; Rice, K.G. Receptor mediated glycotargeting. J. Drug Target, 1995, 3(2), 111-127.
45. Nag, A.; Ghosh, P.C. Assessment of targeting potential of galactosylated and mannosylated sterically stabilized liposomes to different cell types of mouse liver. J. Drug Target, 1999, 6(6), 427-438.
46. Sharma, A.; Sharma, S.; Khuller, G.K. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother., 2004, 54(4), 761-766.
47. Jain, A.; Agarwal, A.; Majumder, S.; Lariya, N.; Khaya, A.; Agrawal, H.; Majumdar, S.; Agrawal, G.P. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anticancer drug. J. Control Release, 2010, 148(3), 359-367.
48. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Wu, X.Y. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci., 2004, 93(8), 1993-2008.
49. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Xue, H.Y.; Babakhanian, K.; Wu, X.Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther., 2006, 317(3), 1372-1381.
50. Wong, H.L.; Rauth, A.M.; Bendayan, R.; Wu, X.Y. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur. J. Pharm. Biopharm., 2007, 65(3), 300-308.
51. Wong, H.L.; Rauth, A.M.; Bendayan, R.; Manias, J.L.; Ramaswamy, M.; Liu, Z.; Erhan, S.Z.; Wu, X.Y. A new polymerlipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res., 2006, 23(7), 1574-1585.
52. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Wu, X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymerlipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control Release, 2006, 116(3), 275-284.
53. Cheung, R.Y.; Rauth, A.M.; Yu Wu, X. In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations. Anticancer Drugs, 2005, 16(4), 423-433.
54. Cheung, R.Y.; Rauth, A.M.; Ronaldson, P.T.; Bendayan, R.; Wu, X.Y. In vitro toxicity to breast cancer cells of microspheredelivered mitomycin C and its combination with doxorubicin. Eur. J. Pharm. Biopharm., 2006, 62(3), 321-331.
55. Shuhendler, A.J.; O'Brien, P.J.; Rauth, A.M.; Wu, X.Y. On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. Drug Metabol. Drug. Interact., 2007, 22(4), 201-233.
56. Shuhendler, A.J.; Cheung, R.Y.; Manias, J.; Connor, A.; Rauth, A.M.; Wu, X.Y. A novel doxorubicin-mitomycin C coencapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat., 2010, 119(2), 255-269.
57. Yousefpour, P.; Atyabi, F.; Farahani, E.V.; Sakhtianchi, R.; Dinarvand, R. Polyanionic carbohydrate doxorubicin-dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations. Int. J. Nanomedicine, 2011, 6, 1487-1496.
58. Jeong, Y.I.; Chung, K.D.; Choi, K.C. Doxorubicin release from self-assembled nanoparticles of deoxycholic acid-conjugated dextran. Arch. Pharm. Res., 2011, 34(1), 159-167.
59. Deng, W.; Li, J.; Yao, P.; He, F.; Huang, C. Green preparation process, characterization and antitumor effects of doxorubicin-BSA-dextran nanoparticles. Macromol. Biosci., 2010, 10(10), 1224-1234.
60. Bisht, S.; Maitra, A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2009, 1(4),415-425.
61. Du, Y.Z.; Weng, Q.; Yuan, H.; Hu, F.Q. Synthesis and antitumor activity of stearate-a-dextran micelles for intracellular doxorubicin delivery. ACS Nano, 2010, 4(11), 6894-6902.
62. Srinophakun, T.; Boonmee, J. Preliminary Study of Conformation and Drug Release Mechanism of Doxorubicin-Conjugated Glycol Chitosan, via cis-Aconityl Linkage, by Molecular Modeling. Int. J. Mol. Sci., 2011, 12(3), 1672-1683.
63. Jarmila, V.; Vavríková, E. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities--a review. Curr. Pharm. Des., 2011, 17(32), 3596-607.
64. Tiyaboonchai, W. Chitosan nanoparticles: a promising system for drug delivery. Naresuan University Journal, 2003, 11(3), 51-66.
65. Sun, Y.; Wan, A. Preparation of nanoparticles composed of chitosan and its derivatives as delivery systems for macromolecules. J. Applied Poly. Sci., 2007, 105(2), 552-561.
66. Hou, Z.; Zhan, C.; Jiang, Q.; Hu, Q.; Li, L.; Chang, D.; Yang, X.; Wang, Y.; Li, Y.; Ye, S.; Xie, L.; Yi, Y.; Zhang, Q. Both FA-and mPEG-conjugated chitosan nanoparticles for targeted cellular uptake and enhanced tumor tissue distribution. Nanoscale Res. Lett., 2011, 6(1), 563.
67. Zhao, Y.; Sun, Y.; Zang, Z.; Xu, X.; Zhang, Z.; Zhong, L.; Zan, W.; Zhao, Y.; Sun, L. Synthesis and characterization of graft copolymer of chitosan and polyethylene glycol. Mol. Biol. Rep., 2011, 38(4), 2455-2462.
68. Casettari L, Vllasaliu D, Mantovani G, Howdle SM, Stolnik S, Illum L. Effect of PEGylation on the toxicity and permeability enhancement of chitosan. Biomacromolecules, 2010, 11, 2854-2865.
69. Fan, C.; Gao, W.; Chen, Z.; Fan, H.; Li, M.; Deng, F.; Chen, Z. Tumor selectivity of stealth multi-functionalized superparamagnetic iron oxide nanoparticles. Int. J. Pharm., 2011, 404(1-2), 180-190.
70. Yang, L.Q.; Lan, Y.Q.; Guo, H.; Cheng, L.Z.; Fan, J.Z.; Cai, X.; Zhang, L.M., Chen, R.F.; Zhou, H.S. Ophthalmic drug-loaded N, Ocarboxymethyl chitosan hydrogels: synthesis, in vitro and in vivo evaluation. Acta Pharmacol. Sin., 2010, 31(12), 1625-1634.
71. Wang, D.; Mo, J.; Pan, S.; Chen, H.; Zhen, H. Prevention of postoperative peritoneal adhesions by O-carboxymethyl chitosan in a rat cecal abrasion model. Clin. Invest. Med., 2010, 33(4), E254-260.
72. Hyung Park, J.; Kwon, S.; Lee, M.; Chung, H.; Kim, J.H.; Kim, Y.S.; Park, R.W.; Kim, I.S.; Bong Seo, S.; Kwon, I.C.; Young Jeong, S. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials., 2006, 27(1),119-126.
73. Son, Y.J.; Jang, J.S.; Cho, Y.W.; Chung, H.; Park, R.W.; Kwon, I.C.; Kim, I.S.; Park, J.Y.; Seo, S.B.; Park, C.R.; Jeong, S.Y. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J. Control Release, 2003, 91(1-2), 135-145.
74. Tian, Q.; Wang, X.H.; Wang, W.; Zhang, C.N.; Wang, P.; Yuan, Z. Self-Assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid. Nanomedicine, 2011, 8(6), 870-879.
75. Wang, B.; He, C.; Tang, C.; Yin, C. Effects of hydrophobic and hydrophilic modifications on gene delivery of amphiphilic chitosan based nanocarriers. Biomaterials, 2011, 32(20), 4630-4638.
76. Zhang, J.; Chen, X.G.; Li, Y.Y.; Liu, C.S. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomedicine, 2007, 3(4), 258-265.
77. Pruitt, J.D.; Husseini, G.; Rapoport, N.; Pitt, W.G. Stabilization of pluronic P-105 micelles with an interpenetrating network of N, NDiethylacrylamide. Macromolecules, 2000, 33(25), 9306-9309.
78. Naruphontjirakul, P. Development of doxorubicin-core shell O-succinyl chitosan graft pluronic®127 copolymer nanoparticles to treat human cancer. Int. J. Biosci. Biochem. Bioinform., 2011, 1(2), 131-136.
79. Hu, H.; Yu, J.; Li, Y.; Zhao, J.; Dong, H. Engineering of a novel pluronic F127/graphene nanohybrid for pH responsive drug delivery. J. Biomed. Mater. Res. A., 2012, 100(1), 141-148.
80. Gao, Q.; Liang, Q.; Yu, F.; Xu, J.; Zhao, Q.; Sun, B. Synthesis and characterization of novel amphiphilic copolymer stearic acid-coupled F127 nanoparticles for nano-technology based drug delivery system. Colloids Surf. B. Biointerfaces, 2011, 88(2), 741-748.
81. Oh, K.S.; Um, Y.S.; Lee, J.H.; Cho, S.H.; Lee, K.E.; Han, S.S.; Kim, D.; Yuk, S.H. Core/shell nanoparticles for pH-sensitive delivery of doxorubicin. J. Nanosci. Nanotechnol., 2010, 10(10), 6967-6971.
82. Shachaf, Y.; Gonen-Wadmany, M.; Seliktar, D. The biocompatibility of PluronicF127 fibrinogen-based hydrogels. Biomaterials, 2010, 31(10), 2836-2847.
83. You, J.; Hu, F.Q.; Du, Y.Z.; Yuan, H. Polymeric micelles with glycolipid-like structure and multiple hydrophobic domains for mediating molecular target delivery of paclitaxel. Biomacromolecules, 2007, 8(8), 2450-2456.
84. Hu, F.Q.; Liu, L.N.; Du, Y.Z.; Yuan, H. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials, 2009, 30(36), 6955-6963.
85. Olsvik, O.; Popovic, T.; Skjerve, E.; Cudjoe, K.S.; Hornes, E.; Ugelstad, J.; Uhlen, M. Magnetic separation techniques in diagnostic microbiology. Clin. Microbiol. Rev., 1994, 7(1), 43-54.
86. Bulte, J.W.; Douglas, T.; Witwer, B.; Zhang, S. C.; Strable, E.; Lewis, B.K.; Zywicke, H.; Miller, B.; van Gelderen, P.; Moskowitz, B.M.; Duncan, I.D.; Frank, J.A. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat. Biotechnol., 2001, 19(12), 1141-1147.
87. Scherer, F.; Anton, M.; Schillinger, U.; Henke, J.; Bergemann, C.; Kruger, A.; Gansbacher, B.; Plank, C. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther., 2002, 9(2), 102-109.
88. Wang, Y.X.; Hussain, S.M.; Krestin, G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol., 2001, 11(11), 2319-2331.
89. Johannsen, M.; Gneveckow, U.; Eckelt, L.; Feussner, A.; Waldofner, N.; Scholz, R.; Deger, S.; Wust, P.; Loening, S.A.; Jordan, A. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int. J. Hyperthermia, 2005, 21(7), 637-647.
90. Lubbe, A.S.; Bergemann, C.; Riess, H.; Schriever, F.; Reichardt, P.; Possinger, K.; Matthias, M.; Dorken, B.; Herrmann, F.; Gurtler, R.; Hohenberger, P.; Haas, N.; Sohr, R.; Sander, B.; Lemke, A.J.; Ohlendorf, D.; Huhnt, W.; Huhn, D. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 1996, 56(20), 4686-4693.
91. Alexiou, C.; Arnold, W.; Klein, R.J.; Parak, F.G.; Hulin, P.; Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lubbe, A.S. Locoregional cancer treatment with magnetic drug targeting. Cancer Res., 2000, 60(23), 6641-6648.
92. Medarova, Z.; Pham, W.; Kim, Y.; Dai, G.; Moore, A. In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int. J. Cancer, 2006, 118(11), 2796-2802.
93. Okon, E.; Pouliquen, D.; Okon, P.; Kovaleva, Z.V.; Stepanova, T.P.; Lavit, S.G.; Kudryavtsev, B.N.; Jallet, P. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Lab. Invest., 1994, 71(6), 895-903.
94. Kohler, N.; Sun, C.; Fichtenholtz, A.; Gunn, J.; Fang, C.; Zhang, M. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small, 2006, 2(6), 785-792.
95. Jain, T.K.; Morales, M.A.; Sahoo, S.K.; Leslie-Pelecky, D.L.; Labhasetwar, V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol. Pharm., 2005, 2(3), 194-205.
96. Schiff, P.B.; Fant, J.; Horwitz, S.B. Promotion of microtubule assembly in vitro by taxol. Nature, 1979, 277(5698), 665-667.
97. Jain, T.K.; Richey, J.; Strand, M.; Leslie-Pelecky, D.L.; Flask, C.A.; Labhasetwar, V. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials, 2008, 29(29), 4012-4021.
98. Tannock, I.F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res., 1989, 49(16), 4373-4384.
99. Wuang, S.C.; Neoh, K.G.; Kang, E.T.; Leckband, D.E.; Pack, D.W. Acid-Sensitive Magnetic Nanoparticles as Potential Drug Depots. AIChE J., 2011, 57(6), 1638-1645.
100. Yallapu, M.M.; Foy, S.P.; Jain, T.K.; Labhasetwar, V. PEGfunctionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm. Res., 2010, 27(11), 2283-2295.
101. Lubbe, A.S.; Alexiou, C.; Bergemann, C. Clinical applications of magnetic drug targeting. J. Surg. Res., 2001, 95(2), 200-206.
102. Torchilin, V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev., 2006, 58(14), 1532-1555.
103. Neuberger, D.; Wong, J. Suspension for intravenous injection: image analysis of scanning electron micrographs of particles to determine size and volume. PDA J. Pharm. Sci. Technol., 2005, 59(3), 187-199.
104. Neuberger, T.; Schopf, B.; Hofmann, H.; Hofmann, M.; von Rechenberg, B. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J. Magn. Magn. Mater., 2005, 293(1), 483-496.
105. Alexiou, C.; Schmid, R.J.; Jurgons, R.; Kremer, M.; Wanner, G.; Bergemann, C.; Huenges, E.; Nawroth, T.; Arnold, W.; Parak, F.G. Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur. Biophys. J., 2006, 35(5), 446-450.
106. Corot, C.; Robert, P.; Idee, J.M.; Port, M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev., 2006, 58(14), 1471-1504.
107. Duguet, E.; Vasseur, S.; Mornet, S.; Devoisselle, J.M. Magnetic nanoparticles and their applications in medicine. Nanomedicine (Lond), 2006, 1(2), 157-168.
108. Moghimi, S.M.; Kissel, T. Particulate nanomedicines. Adv. Drug Deliv. Rev., 2006, 58(14), 1451-1455.
109. Munnier, E.; Cohen-Jonathan, S.; Linassier, C.; Douziech-Eyrolles, L.; Marchais, H.; Souce, M.; Herve, K.; Dubois, P.; Chourpa, I. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting. Int. J. Pharm., 2008, 363(1-2), 170-176.
110. Herve, K.; Douziech-Eyrolles, L.; Munnier, E.; Cohen-Jonathan, S.; Souce, M.; Marchais, H.; Limelette, P.; Warmont, F.; Saboungi, M.L.; Dubois, P.; Chourpa, I. The development of stable aqueous suspensions of PEGylated SPIONs for biomedical applications. Nanotechnology, 2008, 19(46), 465608-465615.
111. Harris, J.M.; Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2003, 2(3), 214-221.
112. Gautier, J.; Munnier, E.; Paillard, A.; Herve, K.; Douziech-Eyrolles, L.; Souce, M.; Dubois, P.; Chourpa, I. A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting. Int. J. Pharm., 2012, 423(1), 16-25.
113. Alakhov, V.; Moskaleva, E.; Batrakova, E.V.; Kabanov, A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem., 1996, 7(2), 209-216.
114. Venne, A.; Li, S.; Mandeville, R.; Kabanov, A.; Alakhov, V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res., 1996, 56(16), 3626-3629.
115. Batrakova, E.V.; Li, S.; Elmquist, W.F.; Miller, D.W.; Alakhov, V.Y.; Kabanov, A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br. J. Cancer, 2001, 85(12), 1987-1997.
116. Kabanov, A.V.; Batrakova, E.V.; Alakhov, V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug. Deliv. Rev., 2002, 54(5), 759-779.
117. Batrakova, E.V.; Kelly, D.L.; Li, S.; Li, Y.; Yang, Z.; Xiao, L.; Alakhova, D.Y.; Sherman, S.; Alakhov, V.Y.; Kabanov, A.V. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol. Pharm., 2006, 3(2), 113-123.
118. Vasey, P.A.; Kaye, S.B.; Morrison, R.; Twelves, C.; Wilson, P.; Duncan, R.; Thomson, A.H.; Murray, L.S.; Hilditch, T.E.; Murray, T.; Burtles, S.; Fraier, D.; Frigerio, E.; Cassidy, J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res., 1999, 5(1), 83-94.
119. Vicent, M.J.; Greco, F.; Nicholson, R.I.; Paul, A.; Griffiths, P.C.; Duncan, R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem. Int. Ed. Engl., 2005, 44(26), 4061-4066.
120. Greco, F.; Vicent, M.J.; Gee, S.; Jones, A.T.; Gee, J.; Nicholson, R.I.; Duncan, R. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J. Control Release, 2007, 117(1), 28-39.
121. Fowers, K.D.; Kopecek, J. Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates. Macromol. Biosci., 2012, [Epub ahead of print].
122. Yíhová, B.; Etrych, T.; Yírová, M.; Tomala, J.; Ulbrich, K.; Kováć, M. Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma. J. Drug Target., 2011, 19(10), 890-899.
123. Yang, Y.; Zhou, Z.; He, S.; Fan, T.; Jin, Y.; Zhu, X.; Chen, C.; Zhang, Z.R.; Huang, Y. Treatment of prostate carcinoma with (Galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates. Biomaterials, 2012, 33(7), 2260-2271.
124. Xiang, Q.; Yang, Y.; Zhou, Z.; Zhou, D.; Jin, Y.; Zhang, Z.; Huang, Y. Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells. Eu. J. Pharm. Biopharm., 2011, 80(2), 379-386.
125. Kopansky, E.; Shamay, Y.; David, A. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer. J. Drug Target., 2011, 19(10):933-943.
126. Etrych, T.; Strohalm, J.; Chytil, P.; Yíhová, B.; Ulbrich, K. Novel star HPMA-based polymer conjugates for passive targeting to solid tumors. J. Drug Target., 2011, 19(10):874-889.
127. Dietrich, A.; Tanczos, E.; Vanscheidt, W.; Schopf, E.; Simon, J.C. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur. J. Cancer, 1997, 33(6), 926-930.
128. Ahrens, T.; Assmann, V.; Fieber, C.; Termeer, C.; Herrlich, P.; Hofmann, M.; Simon, J.C. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J. Invest. Dermatol., 2001, 116(1), 93-101.
129. Asplund, T.; Heldin, P. Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res., 1994, 54(16), 4516-4523.
130. Cai, S.; Thati, S.; Bagby, T.R.; Diab, H.M.; Davies, N.M.; Cohen, M.S.; Forrest, M.L. Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J. Control Release, 2010, 146(2), 212-218.
131. Yim, H.; Na, K. Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein overexpressing cancer cells. Biomacromolecules, 2010, 11(9), 2387-2393.
132. Lee, H.; Ahn, C.H.; Park, T.G. Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for targetspecific delivery of doxorubicin. Macromol. Biosci., 2009, 9(4), 336-342.
133. Choi, K.Y.; Yoon, H.Y.; Kim, J.H.; Bae, S.M.; Park, R.W.; Kang, Y.M.; Kim, I.S.; Kwon, I.C.; Choi, K.; Jeong, S.Y.; Kim, K.; Park, J.H. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano, 2011, 5(11):8591-8599.
134. Fischer, J.R.; Harkin, K.R.; Freeman, L.C. Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine a in healthy dogs. Vet. Ther., 2002, 3(4), 465-473.
135. Cao, N.; Feng, S.S. Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials, 2008, 29(28), 3856-3865.
136. Zhang, Z.; Huey Lee, S.; Feng, S.S. Folate-decorated poly(lactideco-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials, 2007, 28(10):1889-1899.
137. Anbharasi, V.; Cao, N.; Feng, S.S. Doxorubicin conjugated to Dalpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J. Biomed. Mater. Res. A., 2010, 94(3), 730-743.
138. Ma, P.; Dong, X.; Swadley, C.L.; Gupte, A.; Leggas, M.; Ledebur, H.C.; Mumper, R.J. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J. Biomed. Nanotechnol., 2009, 5(2), 151-161.
139. Shroff K, Kokkoli E. PEGylated liposomal doxorubicin targeted to_5_1-expressing MDA-MB-231 breast cancer cells. Langmuir, 2012, 28(10), 4729-4736.
140. Gautier, J.; Munnier, E.; Paillard, A.; Hervé, K.; Douziech-Eyrolles, L.; Soucé, M.; Dubois, P.; Chourpa, I. A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting. Int. J. Pharm., 2012, 423(1), 16-25.
141. Anhorn, M.G.; Wagner, S.; Kreuter, J.; Langer, K.; von Briesen, H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug. Chem., 2008, 19(12), 2321-2331.
142. Abbasi, S.; Paul, A.; Shao, W.; Prakash, S. Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment. J. Drug Deliv., 2012, 2012, 686108.
143. Dantuluri, P.R.; Shah, N.M.; Murthy, R.S.R.; Kumar, M.R.S.; Rao, B.S.S. Epirubicin hydrochloride loaded poly (butyl cyanoacrylate) nanoparticles: formulation optimization, characterization and in vitro evaluation on human breast cancer cell lines. In: Nanotechnolog, 2009, Life Sciences, Medicine, Diagnostics, Bio Materials and Composites; Cancer Nanotechnology. CRC Press: Massachusetts, 2009; Vol. 1, pp. 36-39.